[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558495":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":60,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Turku University Hospital","OTHER_GOV",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cisplatin",null,"50 patients receiving cisplatin as the standard care for their underlying malignancy",[13],"Other: Chemotherapy, chemoradiation, radiation therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Cisplatin-based chemoradion therapy in the head and neck region","50 patients receiving cisplatin-based chemoradiation therapy in the head and neck region as the standard care for their underlying malignancy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Head and neck region radiation therapy","50 patient receiving head and neck region radiation therapy as the standard care for their underlying malignancy",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Oxaliplatin","50 patients receiving oxaliplatin as the standard care for their underlying malignancy",[13],{"label":27,"type":10,"description":28,"interventionNames":10},"Control","50 healthy volunteers who have never received any ototoxic medications",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"OTHER","Chemotherapy, chemoradiation, radiation therapy","Cancer treatment",[9,15,19,23],[36],{"name":37,"affiliation":5,"role":38},"Tytti Willberg, PhD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","+358 2 313 5979","tytti.willberg@varha.fi",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Turku","Southwest Finland","20521","Finland","FI",{"type":53,"coordinates":54},"Point",[55,56],22.26869,60.45148,{"lat":56,"lon":55},[59],{"name":37,"role":41,"phone":42,"phoneExt":10,"email":43},{"type":38,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Tytti Willberg","Principal Investigator","100558495","the-effect-of-cancer-treatments-on-speech-perception-in-noise-cognition-and-hearing-related-quality-of-life-100558495",false,"NCT06551857","The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life","CaSPiN","Inclusion Criteria:\n\n* written informed consent\n* native Finnish speaker\n* age-normative hearing\n* for participants in the treatment arms: diagnosis of a malignancy that will be treated with curative intent with any of the following: 1) Cisplatin as the main chemotherapeutic agent, 2) oxaliplatin as the main chemotherapeutic agent, 3) cisplatin-based chemoradiation therapy in the head and neck region, 4) radiation therapy in the head and neck region\n\nExclusion Criteria:\n\n* inability to provide written informed consent\n* Current or prior major otological condition that has affected or has had the potential to affect hearing\n* Conductive or asymmetric sensorineural HL of any severity\n* Severe sensorineural HL\n* Prior malignancy treated with chemotherapeutics or radiation therapy\n* Prior use of ototoxic medications\n* Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the trial, or may influence the result of the trial.\n* Any condition that, in the opinion of the investigator, would interfere with adherence to the trial requirements.\n\nFor participants in the treatment arms:\n\n* Allergy or hypersensitivity to trial medications or their ingredients\n* Pregnancy or breast-feeding, aim of becoming pregnant during the trial.",true,"ALL","18 Years","75 Years",{"count":75,"type":76},250,"ESTIMATED","OBSERVATIONAL","The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.",[80,81,82,83],"Cancer","Hearing Loss Ototoxic","Cognitive Decline","Quality of Life",[85,86,87,88,89,90,91],"speech perception in noise","ototoxicity","hearing loss","cancer","cisplatin","oxaliplatin","cognition","2025-04-12",{"date":94,"type":95},"2025-04-16","ACTUAL",{"date":97,"type":95},"2024-10-02",{"date":99,"type":76},"2030-12-31",{"name":5,"class":6},1]